Literature DB >> 7932541

Decapeptide agonists of human C5a: the relationship between conformation and spasmogenic and platelet aggregatory activities.

S D Sanderson1, L Kirnarsky, S A Sherman, J A Ember, A M Finch, S M Taylor.   

Abstract

A series of decapeptide analogues corresponding to the C-terminal region of human C5a anaphylatoxin (C5a65-74) was synthesized with residue substitutions to restrict conformational flexibility in the C-terminus. These conformationally constrained peptides behaved as agonists of C5a in spasmogenic assays (smooth muscle contraction in human fetal artery, guinea pig ileum, and guinea pig lung parenchyma) as well as guinea pig platelet aggregation. There were significant correlations in the potencies of these peptides between the various assays. A structure-function analysis led to the identification of a preferred backbone conformation that correlated with the expression of these biological responses. These backbone structural motifs were consistent with a helix-like conformation for residues 65-69, an elongated structure for residues 70-71, and a beta-turn of either type II or type V for residues (71)72-74. The most potent of these agonists expressed almost 5% of the potency of natural C5a.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7932541     DOI: 10.1021/jm00045a023

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.

Authors:  Shailendra B Tallapaka; Bala V K Karuturi; Pravin Yeapuri; Stephen M Curran; Yogesh A Sonawane; Joy A Phillips; D David Smith; Sam D Sanderson; Joseph A Vetro
Journal:  Int J Pharm       Date:  2019-05-08       Impact factor: 5.875

2.  Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes.

Authors:  T M Woodruff; A J Strachan; S D Sanderson; P N Monk; A K Wong; D P Fairlie; S M Taylor
Journal:  Inflammation       Date:  2001-06       Impact factor: 4.092

3.  Pharmacological characterization of antagonists of the C5a receptor.

Authors:  N J Paczkowski; A M Finch; J B Whitmore; A J Short; A K Wong; P N Monk; S A Cain; D P Fairlie; S M Taylor
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

4.  Antagonistic peptides against human anaphylatoxin C5a.

Authors:  Y Kaneko; N Okada; L Baranyi; T Azuma; H Okada
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

5.  Targeted Amino Acid Substitution Overcomes Scale-Up Challenges with the Human C5a-Derived Decapeptide Immunostimulant EP67.

Authors:  Abdulraman M Alshammari; D David Smith; Jake Parriott; Jason P Stewart; Stephen M Curran; Russell J McCulloh; Peter A Barry; Smita S Iyer; Nicholas Palermo; Joy A Phillips; Yuxiang Dong; Donald R Ronning; Jonathan L Vennerstrom; Sam D Sanderson; Joseph A Vetro
Journal:  ACS Infect Dis       Date:  2020-04-13       Impact factor: 5.084

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.